FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * FINE N SCOTT 2. Issuer Name and Ticker or Trading Symbol Cyclo Therapeutics, Inc. [ CYTH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)         (First)         (Middle)
6714 NW 16TH STREET, SUITE B		 3. Date of Earliest Transaction (MM/DD/YYYY)
1/19/2022
(Street)
GAINESVILLE, FL 32163
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  1/19/2022    P    5000  A $3.89 (1) 134666  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported is a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $3.87 to $3.89, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the foregoing ranges.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FINE N SCOTT
6714 NW 16TH STREET, SUITE B
GAINESVILLE, FL 32163		 X
Chief Executive Officer

Signatures
/s/ N. Scott Fine 1/19/2022
**Signature of Reporting Person Date
Cyclo Therapeutics (QB) (USOTC:CTDH)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Cyclo Therapeutics (QB) Charts.
Cyclo Therapeutics (QB) (USOTC:CTDH)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Cyclo Therapeutics (QB) Charts.